Skip to content

Nasdaq · CIK 0001754068

KLRS Kalaris Therapeutics, Inc.

Insider trading from SEC Form 4. Last filing Apr 11, 2025. Close $2.36 on Oct 9, 2026, 0% from the 52-week low and -79% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company

Price and insider trades, last year

KLRSOct 9, 2026 · close 2.36

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Kalaris Therapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
25WeakBrett R Hagen
Chief Accounting Officer
sell
$8,135
907 shares
-32%-
30WeakEdward Miller
General Counsel
sell
$1,068
106 shares
-2%-
30WeakBrett R Hagen
Chief Accounting Officer
sell
$967
96 shares
-3%-
30WeakVikas Sinha
See Remarks
sell
$3,053
303 shares
-1%-
30WeakVikas Sinha
See Remarks
sell
$1,226
129 shares
-0%-
30WeakBrett R Hagen
Chief Accounting Officer
sell
$342
36 shares
-1%-
30WeakEdward Miller
General Counsel
sell
$494
52 shares
-1%-
30WeakVikas Sinha
See Remarks
sell
$431
979 shares
-0%-
30WeakBrett R Hagen
Chief Accounting Officer
sell
$146
332 shares
-0%-
30WeakEdward Miller
General Counsel
sell
$180
409 shares
-0%-
40ModerateDiana Brainard
Chief Executive Officer
sell
$4,775
8,706 shares
-1%-
30WeakEdward Miller
General Counsel
sell
$237
432 shares
-0%-
30WeakVikas Sinha
See Remarks
sell
$1,748
3,186 shares
-0%-
30WeakBrett R Hagen
Chief Accounting Officer
sell
$304
554 shares
-1%-
30WeakVikas Sinha
See Remarks
sell
$4,442
5,136 shares
-0%-
30WeakBrett R Hagen
Chief Accounting Officer
sell
$1,431
1,655 shares
-2%-
30WeakEdward Miller
General Counsel
sell
$1,965
2,272 shares
-1%-
40ModerateDiana Brainard
Chief Executive Officer
sell
$9,176
10,609 shares
-1%-
30WeakEdward Miller
General Counsel
sell
$1,083
1,401 shares
-1%-
40ModerateDiana Brainard
Chief Executive Officer
sell
$7,597
9,752 shares
-1%-
30WeakBrett R Hagen
Chief Accounting Officer
sell
$746
965 shares
-1%-
30WeakVikas Sinha
See Remarks
sell
$2,649
3,428 shares
-0%-

Transactions

The last 52 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Apr 10, 2025Srinivas Akkaraju
director, owner
AGrant or award
Stock Option (Right to Buy)derivative
+18,000$0.00$018,000Apr 11, 2025
Apr 10, 2025Anthony P Adamis
director
AGrant or award
Stock Option (Right to Buy)derivative
+18,000$0.00$018,000Apr 11, 2025
Apr 10, 2025Samir Chandrakant Patel
director
AGrant or award
Stock Option (Right to Buy)derivative
+18,000$0.00$018,000Apr 11, 2025
Apr 10, 2025Andrew Oxtoby
See Remarks
AGrant or award
Stock Option (Right to Buy)derivative
+287,000$0.00$0287,000Apr 11, 2025
Apr 10, 2025Leone D Patterson
director
AGrant or award
Stock Option (Right to Buy)derivative
+18,000$0.00$018,000Apr 11, 2025
Apr 10, 2025Morana Jovan-Embiricos
director
AGrant or award
Stock Option (Right to Buy)derivative
+18,000$0.00$018,000Apr 11, 2025
Apr 10, 2025David Hallal
director
AGrant or award
Stock Option (Right to Buy)derivative
+18,000$0.00$018,000Apr 11, 2025
Apr 10, 2025Brett R Hagen
Chief Accounting Officer
AGrant or award
Stock Option (Right to Buy)derivative
+50,262$0.00$050,262Apr 11, 2025
Apr 10, 2025Napoleone Ferrara
director
AGrant or award
Stock Option (Right to Buy)derivative
+18,000$0.00$018,000Apr 11, 2025
Apr 10, 2025Matthew Feinsod
Chief Medical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+70,551$0.00$070,551Apr 11, 2025
Apr 10, 2025Michael Dybbs
director
AGrant or award
Stock Option (Right to Buy)derivative
+18,000$0.00$018,000Apr 11, 2025
Apr 10, 2025Matthew Feinsod
Chief Medical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+101,000$0.00$0101,000Apr 11, 2025
Mar 26, 2025Brett R Hagen
Chief Accounting Officer
SOpen-market sale
Common Stock
-907$8.97$8,1351,925Mar 27, 2025
Mar 18, 2025Anthony P Adamis
director
AGrant or award
Stock Option (right to buy)derivative
+19,484--19,484Mar 18, 2025
Mar 18, 2025Srinivas Akkaraju
director, owner
AGrant or award
Common Stockindirect: See footnote
+11,444,503--11,444,503Mar 18, 2025
Mar 18, 2025Matthew Feinsod
Chief Medical Officer
AGrant or award
Common Stock
+4,030--4,030Mar 18, 2025
Mar 18, 2025Napoleone Ferrara
director
AGrant or award
Common Stock
+504,000--504,000Mar 18, 2025
Mar 18, 2025Andrew Oxtoby
See Remarks
AGrant or award
Stock Option (right to buy)derivative
+476,611--476,611Mar 18, 2025
Mar 18, 2025Samir Chandrakant Patel
director
AGrant or award
Common Stock
+252,000--252,000Mar 18, 2025
Mar 18, 2025Anthony P Adamis
director
AGrant or award
Stock Option (right to buy)derivative
+12,989--12,989Mar 18, 2025
Mar 18, 2025Samir Chandrakant Patel
director
AGrant or award
Common Stockindirect: See footnote
+100,800--100,800Mar 18, 2025
Mar 18, 2025Matthew Feinsod
Chief Medical Officer
AGrant or award
Stock Option (right to buy)derivative
+28,224--28,224Mar 18, 2025
Mar 18, 2025Samir Chandrakant Patel
director
AGrant or award
Stock Option (right to buy)derivative
+105,913--105,913Mar 18, 2025
Feb 21, 2025Edward Miller
General Counsel
SOpen-market sale
Common Stock
-106$10.08$1,0686,517Feb 24, 2025
Feb 21, 2025Brett R Hagen
Chief Accounting Officer
SOpen-market sale
Common Stock
-96$10.08$9672,832Feb 24, 2025
Feb 21, 2025Vikas Sinha
See Remarks
SOpen-market sale
Common Stock
-303$10.08$3,05349,129Feb 24, 2025
Jan 23, 2025Vikas Sinha
See Remarks
SOpen-market sale
Common Stock
-116$9.45$1,09749,445Jan 27, 2025
Jan 23, 2025Edward Miller
General Counsel
SOpen-market sale
Common Stock
-47$9.45$4446,628Jan 27, 2025
Jan 23, 2025Brett R Hagen
Chief Accounting Officer
SOpen-market sale
Common Stock
-32$9.45$3032,932Jan 27, 2025
Jan 23, 2025Brett R Hagen
Chief Accounting Officer
SOpen-market sale
Common Stock
-4$9.94$402,928Jan 27, 2025
Jan 23, 2025Vikas Sinha
See Remarks
SOpen-market sale
Common Stock
-13$9.94$12949,432Jan 27, 2025
Jan 23, 2025Edward Miller
General Counsel
SOpen-market sale
Common Stock
-5$9.94$506,623Jan 27, 2025
Jan 10, 2025Vikas Sinha
See Remarks
SOpen-market sale
Common Stock
-979$0.44$4311,139,915Jan 13, 2025
Jan 10, 2025Brett R Hagen
Chief Accounting Officer
SOpen-market sale
Common Stock
-332$0.44$14668,174Jan 13, 2025
Jan 10, 2025Edward Miller
General Counsel
SOpen-market sale
Common Stock
-409$0.44$180153,541Jan 13, 2025
Dec 11, 2024Edward Miller
General Counsel
GGift
Common Stock
-57,549$0.00$0153,950Dec 11, 2024
Dec 11, 2024Edward Miller
General Counsel
GGift
Common Stockindirect: See footnote
+57,549$0.00$0346,348Dec 11, 2024
Nov 19, 2024Brett R Hagen
Chief Accounting Officer
SOpen-market sale
Common Stock
-554$0.55$30468,506Nov 20, 2024
Nov 19, 2024Vikas Sinha
See Remarks
SOpen-market sale
Common Stock
-3,186$0.55$1,7481,140,894Nov 20, 2024
Nov 19, 2024Edward Miller
General Counsel
SOpen-market sale
Common Stock
-432$0.55$237211,499Nov 20, 2024
Nov 19, 2024Diana Brainard
Chief Executive Officer
SOpen-market sale
Common Stock
-8,706$0.55$4,775723,363Nov 20, 2024
Nov 5, 2024Vikas Sinha
See Remarks
SOpen-market sale
Common Stock
-5,136$0.86$4,4421,144,080Nov 6, 2024
Nov 5, 2024Brett R Hagen
Chief Accounting Officer
SOpen-market sale
Common Stock
-1,655$0.86$1,43169,060Nov 6, 2024
Nov 5, 2024Edward Miller
General Counsel
SOpen-market sale
Common Stock
-2,272$0.86$1,965211,931Nov 6, 2024
Nov 5, 2024Diana Brainard
Chief Executive Officer
SOpen-market sale
Common Stock
-10,609$0.86$9,176732,069Nov 6, 2024
Oct 21, 2024Edward Miller
General Counsel
SOpen-market sale
Common Stock
-635$0.78$495214,969Oct 23, 2024
Oct 21, 2024Diana Brainard
Chief Executive Officer
SOpen-market sale
Common Stock
-9,752$0.78$7,597742,678Oct 23, 2024
Oct 21, 2024Brett R Hagen
Chief Accounting Officer
SOpen-market sale
Common Stock
-479$0.78$37371,201Oct 23, 2024
Oct 21, 2024Vikas Sinha
See Remarks
SOpen-market sale
Common Stock
-1,546$0.78$1,2041,151,098Oct 23, 2024
Oct 22, 2024Edward Miller
General Counsel
SOpen-market sale
Common Stock
-766$0.77$588214,203Oct 23, 2024
Oct 22, 2024Brett R Hagen
Chief Accounting Officer
SOpen-market sale
Common Stock
-486$0.77$37370,715Oct 23, 2024
Oct 22, 2024Vikas Sinha
See Remarks
SOpen-market sale
Common Stock
-1,882$0.77$1,4451,149,216Oct 23, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

KLRS insider trading: Kalaris Therapeutics, Inc. | InsiderTell